Human monoclonal antibody therapy to prevent hepatitis C virus reinfection of liver transplants: advancing lead monoclonal antibodies into clinical trial Ghent University
Worldwide. 200 million people are infected with the hepatitis C virus (HCV). An estimated 15 million individuals are living with HCV infection wilhin Ihe EU. The economic. health and societal costs of chronic HCV infeclion are significant. HCV is the principal cause of death from liver disease and the leading indication for liver
transplantation. The only treatment for end-stage liver disease is a liver Transplant. yet The ...